Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by steve29caon Feb 27, 2012 11:46pm

419 Views

Post# 19595594

Financing

As of Dec 31/12 cash on hand was $18.8mil

Equity Financing $15 - $17.25 mil

Warrents coming due in 2012 from
.88-$1.50 total potential value to Brigus $8.1 mil

Total about $42 mil without including any income from mining. The buy back from Sandstrom is $36 mil. Maybe things are looking up at the mine and Brigus is planning to buy back the 6% before the Nov 2012 deadline.

Thoughts?

Still would have liked to see a better share price for the financing deal. JMO

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading